Australia Liquid Biopsy Market Size & Outlook, 2023-2030
Australia liquid biopsy market, 2018-2030 (US$M)
Related Markets
Australia liquid biopsy market highlights
- The Australia liquid biopsy market generated a revenue of USD 35.1 million in 2023 and is expected to reach USD 88.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 14.1% from 2024 to 2030.
- In terms of segment, blood sample was the largest revenue generating type in 2023.
- Blood Sample is the most lucrative type segment registering the fastest growth during the forecast period.
Liquid biopsy market data book summary
| Market revenue in 2023 | USD 35.1 million |
| Market revenue in 2030 | USD 88.3 million |
| Growth rate | 14.1% (CAGR from 2023 to 2030) |
| Largest segment | Blood sample |
| Fastest growing segment | Blood Sample |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, Australia accounted for 0.3% of the global liquid biopsy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China liquid biopsy market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 29.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample was the largest segment with a revenue share of 73.22% in 2023. Horizon Databook has segmented the Australia liquid biopsy market based on blood sample covering the revenue growth of each sub-segment from 2018 to 2030.
The Australian liquid biopsy market is expected to grow significantly due to research collaborations and favorable government initiatives. In May 2022, the Australian Cancer Research Foundation (ACRF) launched the Child Cancer Liquid Biopsy Program for children with cancer.
Under this program, simple blood tests provide information about changes in a child with cancer through its journey and whether or not the child is supported well to treatment.
For instance, in November 2022, researchers at UNSW Sydney are focusing on developing less invasive and safer approaches to biopsy tumors, which is the next step in cancer monitoring and detection.
Reasons to subscribe to Australia liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia liquid biopsy market , including forecasts for subscribers. This country databook contains high-level insights into Australia liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia liquid biopsy market size, by type, 2018-2030 (US$M)
Australia Liquid Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
